Final price in Wilson Therapeutics’ initial public offering set at SEK 49 per share – trading on Nasdaq Stockholm commences todayMay 12, 2016
Wilson Therapeutics AB (publ) (“Wilson Therapeutics” or the “Company”), hereby announces the outcome relating to the offering of newly issued shares in the Company (the “Offering”) and listing on Nasdaq Stockholm. The Offering attracted strong interest among Swedish and international investors.
- The final price in the Offering has been set at SEK 49 per share, corresponding to a market capitalization of SEK 1,305 million for the total number of outstanding shares in Wilson Therapeutics, provided that the Over-allotment option (defined below) is fully utilized.
- The Offering was well oversubscribed and the number of shares in the Offering was increased in full, in accordance with the terms of the Offering, by 763,088 newly issued shares, for a total of 8,518,190 shares in the Offering, corresponding to 33.6 percent of the total number of shares outstanding in the Company.
- Furthermore, the Company has granted an over-allotment option corresponding to 15 percent of the number of shares in the Offering (the “Over-allotment option”). If the Over-allotment option is fully utilized, the Offering will comprise 9,795,918 shares in total, corresponding to a total value of the Offering of SEK 480 million, before issue expenses.
- A core group of well renowned investors consisting of the founders of Recipharm Lars Backsell and Thomas Eldered (B&E Participation), The Fourth Swedish National Pension Fund (AP4), Handelsbanken Fonder, Strand Kapitalförvaltning, the existing main shareholders HealthCap, Abingworth, MVM Life Science Partners and NeoMed, as well as the Company’s chairman Andrew Kay, will invest in total approximately SEK 210 million, corresponding to more than half of the Offering.
- Following the completion of the Offering, HealthCap will remain the largest shareholder in Wilson Therapeutics and will, assuming that the Over-allotment option is exercised in full, hold approximately 28.1 percent of the total number of shares in the Company.
- Trading in the Company’s shares on Nasdaq Stockholm commences today, 12 May 2016, under the ticker “WTX” (ISIN code: SE0008293674).
- Trading is conditional until the settlement day, which is expected to be 16 May 2016.
Jonas Hansson, CEO of Wilson Therapeutics comments:
“The IPO has received strong interest both in Sweden and internationally. We are very pleased by the confidence shown in us by current and new investors. Decuprate® has the potential to be the first new product for the treatment of Wilson Disease in more than 50 years and the support we receive from patients, relatives and treating physicians is significant. The IPO gives us the opportunity to continue developing Decuprate® all the way to the market with the goal of offering patients with Wilson Disease a novel therapy that addresses the large medical need that exists.”
ABG Sundal Collier AB, Carnegie Investment Bank AB (publ) and DNB Markets, a part of DNB Bank ASA, are acting as Joint Global Coordinators and Joint Bookrunners in the Offering. Vinge law firm is legal advisor to the Company. Hammarskiöld & Co is legal adviser to the Joint Global Coordinators and Joint Bookrunners.
About Wilson Therapeutics
Wilson Therapeutics is a biopharmaceutical company, based in Stockholm, Sweden that develops novel therapies for patients with rare diseases. Wilson Therapeutics’ product, Decuprate®, is initially being developed as a novel treatment for Wilson Disease and is currently in a Phase II clinical study in Wilson Disease patients.
Wilson Disease is a rare genetic disease that causes serious copper poisoning. Wilson Disease affects approximately one in every 30,000 people worldwide, corresponding to a prevalence of approximately 10,000 patients in the United States and 15,000 patients in the EU.
The active ingredient in Decuprate®, tetrathiomolybdate, is a first-in-class de-coppering agent with a unique mechanism of action that is expected to provide several advantages over existing therapies, such as: a fast removal of copper leading to improved response rates, an improved safety and tolerability profile and a simplified dosing regimen for improved treatment compliance. Decuprate® has been granted Orphan Drug Designation for the treatment of Wilson Disease in the United States and the EU.
For more information contact:
Jonas Hansson, CEO
Tel: +46 (0)70 944 18 77
Anders Martin-Löf, CFO
Tel: +46 (0)70 683 79 77
This announcement is not an offer to sell or a solicitation of any offer to buy any securities issued by Wilson Therapeutics AB (publ) in any jurisdiction where such offer or sale would be unlawful.
In any EEA Member State, other than Sweden, that has implemented Directive 2003/71/EC as amended (together with any applicable implementing measures in any member State, the “Prospectus Directive”), this communication is only addressed to and is only directed at qualified investors in that Member State within the meaning of the Prospectus Directive.
This document and the information contained herein is not for distribution in or into the United States of America. This document does not constitute an offer to sell, or a solicitation of an offer to purchase, any securities in the United States. Any securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of the securities in the United States.
In the United Kingdom, this document and any other materials in relation to the securities described herein is only being distributed to, and is only directed at, and any investment or investment activity to which this document relates is available only to, and will be engaged in only with, “qualified investors” (as defined in section 86(7) of the Financial Services and Markets Act 2000) and who are (i) persons having professional experience in matters relating to investments who fall within the definition of “investment professionals” in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”); or (ii) high net worth entities falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as “relevant persons”). In the United Kingdom, any investment or investment activity to which this communication relates is available only to, and will be engaged in only with, relevant persons. Persons who are not relevant persons should not take any action on the basis of this document and should not act or rely on it.
Any offering of the securities referred to in this announcement will be made by means of a prospectus. This announcement is not a prospectus for the purposes of the Prospectus Directive. A prospectus prepared in accordance with the Prospectus Directive has been published and is held available at www.wilsontherapeutics.com. Investors should not subscribe for any securities referred to in this announcement except on the basis of information contained in the aforementioned prospectus.
This communication contains forward-looking statements that reflect the Company’s intentions, beliefs, or current expectations about and targets for the Company’s future results of operations, financial condition, liquidity, performance, prospects, anticipated growth, strategies and opportunities and the markets in which the Company operates, including with respect to prospects for pharmaceutical treatments and studies, including Decuprate®. Forward-looking statements are statements that are not historical facts and may be identified by words such as “believe”, “expect”, “anticipate”, “intend”, “may”, “plan”, “estimate”, “will”, “should”, “could”, “aim” or “might”, or, in each case, their negative, or similar expressions. The forward-looking statements in this release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurances that they will materialize or prove to be correct. Because these statements are based on assumptions or estimates and are subject to risks and uncertainties, the actual results or outcome could differ materially from those set out in the forward-looking statements as a result of many factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The Company does not guarantee that the assumptions underlying the forward-looking statements in this presentation are free from errors nor does it accept any responsibility for the future accuracy of the opinions expressed in this presentation or any obligation to update or revise the statements in this presentation to reflect subsequent events. Undue reliance should not be placed on the forward-looking statements in this document. The information, opinions and forward-looking statements contained in this communication speak only as at its date and are subject to change without notice. The Company does not undertake any obligation to review, update, confirm or to release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this communication.